Saturna Capital’s Unity Biotechnology UBX Stock Holding History

Saturna Capital’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$44K	–	184
2021 Q4	$44K	Hold	3,000	–	–	﹤0.01%	173
2021 Q3	$90K	Hold	3,000	–	–	﹤0.01%	173
2021 Q2	$139K	Hold	3,000	–	–	﹤0.01%	174
2021 Q1	$180K	Sell	3,000 -3,000	-50%	-$205K	﹤0.01%	164
2020 Q4	$314K	Buy	6,000 +3,000	+100%	+$145K	0.01%	150
2020 Q3	$104K	Buy	3,000 +700	+30%	+$44.3K	﹤0.01%	160
2020 Q2	$200K	Hold	2,300	–	–	0.01%	163
2020 Q1	$133K	Buy	2,300 +200	+10%	+$12.6K	﹤0.01%	168
2019 Q4	$151K	Hold	2,100	–	–	﹤0.01%	187
2019 Q3	$128K	Buy	+2,100	New	+$149K	﹤0.01%	185

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Saturna Capital's UBX Position: Q1 2022 in Review

Saturna Capital sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 3,000 shares — an estimated $44K sold.

Saturna Capital first reported a position in UBX in Q3 2019 and held it in 10 quarters. The position peaked at $314K in Q4 2020. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

Saturna Capital reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
Saturna Capital sold 3,000 Unity Biotechnology shares in Q1 2022, an estimated $44K.
Saturna Capital first reported a position in Unity Biotechnology in Q3 2019 and held it in 10 quarters.
Saturna Capital's Unity Biotechnology position peaked at $314K in Q4 2020.
70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on Saturna Capital's 13F filing for Q1 2022, filed 10 May 2022.